GQG Partners LLC Invests $822.99 Million in CVS Health Corporation $CVS

GQG Partners LLC purchased a new stake in CVS Health Corporation (NYSE:CVS) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 7,955,411 shares of the pharmacy operator’s stock, valued at approximately $822,989,000. CVS Health comprises 1.5% of GQG Partners LLC’s portfolio, making the stock its 21st largest holding.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CVS. Sei Investments Co. grew its position in shares of CVS Health by 17.4% during the 2nd quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock worth $62,474,000 after buying an additional 134,535 shares during the period. The Manufacturers Life Insurance Company boosted its stake in CVS Health by 1.2% in the second quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock valued at $77,353,000 after acquiring an additional 13,329 shares during the last quarter. Treasurer of the State of North Carolina grew its holdings in CVS Health by 1.3% during the 2nd quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock worth $40,358,000 after acquiring an additional 7,588 shares during the period. HUB Investment Partners LLC raised its position in shares of CVS Health by 25.0% during the 2nd quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock valued at $1,039,000 after acquiring an additional 3,011 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in shares of CVS Health by 8.0% in the 2nd quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock valued at $111,017,000 after purchasing an additional 119,439 shares during the period. 80.66% of the stock is owned by institutional investors.

CVS Health Stock Down 0.7%

Shares of CVS stock opened at $93.01 on Friday. CVS Health Corporation has a 12-month low of $69.51 and a 12-month high of $110.68. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. The firm has a fifty day moving average of $102.02 and a 200-day moving average of $88.86. The company has a market capitalization of $118.96 billion, a price-to-earnings ratio of 24.61, a P/E/G ratio of 0.85 and a beta of 0.61.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The firm had revenue of $106.10 billion during the quarter, compared to analysts’ expectations of $100.03 billion. During the same quarter in the prior year, the company earned $1.81 EPS. The company’s revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities research analysts predict that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were issued a dividend of $0.665 per share. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. CVS Health’s dividend payout ratio (DPR) is presently 70.37%.

Analysts Set New Price Targets

CVS has been the subject of a number of recent analyst reports. Weiss Ratings upgraded CVS Health from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 5th. Royal Bank Of Canada raised their target price on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a report on Thursday, July 9th. Morgan Stanley upped their price target on CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Argus increased their price target on shares of CVS Health from $104.00 to $114.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, DA Davidson lifted their price objective on shares of CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Twenty-two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $107.17.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.